Business Combinations (Narrative) (Details)	3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Jul. 04, 2021 USD ($) employees	Jul. 05, 2020 USD ($)	Jul. 04, 2021 USD ($) employees	Jul. 05, 2020 USD ($)	Oct. 03, 2021 USD ($) employees	Jan. 03, 2021 USD ($) employees	Apr. 04, 2021 USD ($)	Apr. 05, 2020 USD ($)	Dec. 29, 2019 USD ($)
Business Acquisition [Line Items]
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions			1 year
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 3,334,000	$ 13,726,000	$ 3,334,000	$ 13,726,000		$ 2,953,000	$ 3,124,000	$ 22,777,000	$ 35,481,000
Total transaction costs	(10,600,000)	(5,200,000)	(15,100,000)	(7,100,000)
Goodwill	3,844,070,000		3,844,070,000			3,447,114,000
Business Combination, Contingent Consideration, Liability, Current	3,200,000		3,200,000			2,900,000
Business Combination, Contingent Consideration, Liability, Noncurrent	100,000		100,000			100,000
Foreign Currency Transaction Gain (Loss), before Tax	800,000	6,400,000	(600,000)	(3,500,000)
Interest Expense	16,750,000	11,586,000	30,876,000	25,251,000
Business Combination, Contingent Consideration, Liability	3,300,000		3,300,000			3,000,000.0
Fiscal Year 2021 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred			703,180,000
Cash Acquired			157,278,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	35,265,000		35,265,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	13,293,000		13,293,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	15,187,000		15,187,000
Cash paid to the shareholders			859,548,000
Business Combination, Consideration Transferred, Liabilities Incurred			$ 910,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			11 years 10 months 24 days
Goodwill	428,923,000		$ 428,923,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	44,417,000		44,417,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$ 703,180,000		$ 703,180,000
Oxford Immunotec [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees	275		275
Foreign Currency Transaction Gain (Loss), before Tax			$ (5,400,000)
Interest Expense			$ 200,000
Nexcelom Bioscience [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees	130		130
Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments						384,000
Business Combination, Consideration Transferred						412,097,000
Cash Acquired						(26,840,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets						35,532,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment						20,302,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets						18,114,000
Cash paid to the shareholders						437,661,000
Business Combination, Consideration Transferred, Liabilities Incurred						$ 1,660,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						11 years
Goodwill						$ 221,960,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt						45,171,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						$ 412,097,000
Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees						400
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold	$ (6,300,000)	$ (5,600,000)	$ (11,700,000)	$ (6,700,000)
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,952,135,000		1,952,135,000			$ 1,691,227,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	1,891,935,000		1,891,935,000			1,755,887,000
Core Technology [Member] | Fiscal Year 2021 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	193,260,000		193,260,000
Core Technology [Member] | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						65,730,000
Customer Relationships [Member] | Fiscal Year 2021 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	104,270,000		104,270,000
Customer Relationships [Member] | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						108,523,000
Trade Names [Member] | Fiscal Year 2021 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 26,070,000		26,070,000
Trade Names [Member] | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						5,580,000
Subsequent Event [Member] | SIRION Biotech [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees					50
Subsequent Event [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees					700
Euro Member Countries, Euro | Subsequent Event [Member] | SIRION Biotech [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					$ 80,000,000.0
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					72,000,000.0
United States of America, Dollars | Fiscal Year 2021 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			860,500,000
United States of America, Dollars | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			590,900,000
United States of America, Dollars | Nexcelom Bioscience [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			267,100,000
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			$ 2,500,000
United States of America, Dollars | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						438,900,000
United States of America, Dollars | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						399,800,000
United States of America, Dollars | Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						39,100,000
United States of America, Dollars | Subsequent Event [Member] | SIRION Biotech [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					94,800,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					85,300,000
United States of America, Dollars | Subsequent Event [Member] | Immunodiagnostic Systems [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					155,000,000.0
United States of America, Dollars | Subsequent Event [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					5,250,000,000
United Kingdom, Pounds | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						$ 296,000,000.0
United Kingdom, Pounds | Subsequent Event [Member] | Immunodiagnostic Systems [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					$ 110,000,000.0